Quetiapine for Elderly Patients With Psychotic Disorders

[1]  L. Schneider,et al.  QUETIAPINE MAY REDUCE HOSTILITY IN PATIENTS WITH PSYCHOSES RELATED TO ALZHEIMER's DISEASE , 1999 .

[2]  J. Friedman,et al.  Quetiapine for the treatment of drug‐induced psychosis in Parkinson's disease , 1999 .

[3]  D. Q. Mcmanus,et al.  Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. , 1999, The Journal of clinical psychiatry.

[4]  M. Parsa,et al.  Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. , 1998, The Journal of neuropsychiatry and clinical neurosciences.

[5]  J. McKellar,et al.  ‘seroquel’®: An effective atypical antipsychotic with no greater EPS than placebo across the full dose range , 1998, Schizophrenia Research.

[6]  S. Potkin,et al.  561 Pharmacokinetics and safety of lithium co-administered with ‘seroquel’ (quetiapine) , 1997, Schizophrenia Research.

[7]  B. J. Ewing,et al.  566 The effect of phenytoin and cimetidine on the pharmacokinetics of seroquel , 1997, Schizophrenia Research.

[8]  S. Grimm,et al.  559 In vitro prediction of potential metabolic drug interactions for seroquel , 1997, Schizophrenia Research.

[9]  B. J. Ewing,et al.  565 Pharmacokinetics of ‘seroquel’ (quetiapine) in hepatic and renal insufficiency , 1997, Schizophrenia Research.

[10]  S. Hirsch,et al.  ICI 204, 636: A New Atypical Antipsychotic Drug , 1996, British Journal of Psychiatry.

[11]  J. Goldstein,et al.  ICI 204,636 (SEROQUEL™): A Dibenzothiazepine Atypical Antipsychotic. Review of Preclinical Pharmacology and Highlights of Phase II Clinical Trials , 1995 .

[12]  D. Casey.  Drug Evaluations: Drug Evaluation Central & Peripheral Nervous Systems: ‘Seroquel’ (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic , 1996 .